Suven Life Sciences gets nod to form wholly owned subsidiary in US

Suven Life Sciences has received approval to form Wholly Owned Subsidiary (WOS) Company — Suven Pharma, Inc. a Delaware Company in US under CRAMS Division. The Board of Directors of the Company at its meeting held on March 09, 2019 has approved the same.

The board also approved investment of $75 million in the said WOS for new business opportunities and acquisitions etc.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.